Squarepoint Ops LLC Increases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Squarepoint Ops LLC raised its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 88.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,344 shares of the company’s stock after purchasing an additional 19,407 shares during the period. Squarepoint Ops LLC’s holdings in GoodRx were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GDRX. Beacon Capital Management LLC purchased a new position in GoodRx in the first quarter valued at about $28,000. Plato Investment Management Ltd purchased a new position in GoodRx in the second quarter valued at about $43,000. Gerber LLC purchased a new position in GoodRx in the fourth quarter valued at about $75,000. EntryPoint Capital LLC boosted its holdings in GoodRx by 165.2% in the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after acquiring an additional 11,548 shares in the last quarter. Finally, Syon Capital LLC acquired a new position in shares of GoodRx during the fourth quarter valued at about $168,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Up 0.3 %

GoodRx stock opened at $6.90 on Friday. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. GoodRx Holdings, Inc. has a 12 month low of $4.14 and a 12 month high of $9.26. The stock’s 50 day simple moving average is $7.44 and its two-hundred day simple moving average is $7.58. The firm has a market cap of $2.62 billion, a PE ratio of -53.08, a P/E/G ratio of 4.44 and a beta of 1.37.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The company had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. During the same quarter in the prior year, the company posted $0.02 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. Analysts anticipate that GoodRx Holdings, Inc. will post 0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a report on Friday, August 16th. UBS Group cut their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Finally, Citigroup cut their price objective on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, GoodRx presently has an average rating of “Moderate Buy” and an average target price of $9.36.

Insiders Place Their Bets

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.17% of the company’s stock.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.